Segmental Arterial Mediolysis: A Vasculitis Mimic

Saira Bilal1 Ayad Alkhatib1 E. Blair Solow1 Sanjeeva P. Kalva2

1Division of Rheumatic Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States
2Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, United States

Address for correspondence Saira Bilal, MD, Division of Rheumatology, Department of Medicine, George Washington University School of Medicine & Health Sciences, 2300 M St NM, Washington, DC 20037, United States (e-mail: sbilal@mfa.gwu.edu).

Background Segmental arterial mediolysis (SAM) is a rare noninflammatory vasculopathy. The purpose of this report is to describe the clinical data of six patients diagnosed with SAM, discuss key elements for diagnosis, and highlight the differences between SAM and vasculitis. We also propose a modification to the criteria developed by Kalva et al for the diagnosis of SAM.

Methods This is a retrospective study approved by the Institutional Review Board and included patients diagnosed with SAM between January 2008 and December 2016. Eleven patients were identified, of whom six (four males with a median age of 59.5 years) had complete data per the guidelines proposed by Kalva et al and were thus included. Data on patient’s clinical presentation, laboratory and imaging findings, and outcomes were collected.

Results Presenting symptoms included abdominal pain, flank pain, and bloody stools. Five patients had negative antinuclear antibodies (ANAs) and one had positive ANAs with negative subserologies. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were normal except for an elevated CRP in two patients with organ infarction. The superior mesenteric and renal arteries were most commonly involved. The most common vascular abnormalities were dissection, pseudoaneurysm, thrombosis, and wall thickening. Two patients received endovascular repair for hepatic artery aneurysms. During the follow-up (range: 3–36 months), two patients developed a new aneurysm or dissection.

Conclusion The long-term prognosis of SAM appears to be favorable. Vascular intervention is only needed for patients with impending vascular compromise. We propose that the criteria developed by Kalva et al could be modified to include patients with elevated ANA but negative subserologies and elevated CRP and ESR in the presence of organ infarction.
modifications to the criteria suggested by Kalva et al for the diagnosis of SAM.

Methods
This retrospective study was approved by the Institutional Review Board and performed at a large tertiary institution comprising a 450-bed university academic medical center hospital and a 999-bed county hospital. The requirement to obtain an informed consent for this retrospective study was waived, and the health records of patients included in this study were maintained according to the Health Insurance Portability and Accountability Act (HIPAA). The electronic medical records of these two hospitals were searched for patients with a diagnosis of SAM. There were 11 patients with a diagnosis of SAM during the years 2008 to 2016. The diagnosis of SAM was made using the institutional guidelines proposed by Kalva et al based on clinical, serological, and imaging findings. Five patients were excluded from this study due to incomplete data. The electronic medical records of the remaining six patients were reviewed. Data on patient demographics, clinical presentation, laboratory values, radiological findings on imaging studies, and patient outcomes were extracted.

Results
Clinical Presentation
There were four men and two women in our study cohort. The median age at presentation was 59.5 years (range: 40–73 years). The most common presentation was generalized abdominal pain. Patients also reported epigastric pain, intermittent right upper quadrant and lower chest pain, sudden onset unilateral flank and groin pain, bloody stools, and nausea (Table 1). No constitutional symptoms such as fever, unintentional weight loss, and fatigue were observed prior to or at the time of the presentation. None of the patients reported similar presentations in the past. One patient had a known history of hypertension, and one was found to have factor V Leiden mutation. One patient had a history of methamphetamine use. No known history of autoimmune disease was noted in these patients.

Laboratory Findings
Five patients had a negative ANA. One patient had a positive ANA; however, all subserologies for systemic autoimmune disease were negative. Inflammatory markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were available in all patients. Elevated CRP in two patients was attributed to hepatic and renal infarction. Myeloperoxidase and proteinase 3, which are commonly seen in small vessel vasculitis, were negative in five patients. Hepatitis serologies were available in one patient and were negative in one. Two patients were evaluated by a genetic specialist: one patient had genetic testing and was negative for COL3A1 mutation, and the second patient opted out of genetic testing but was confirmed to not have any clinical features suggestive of Ehlers–Danlos’s syndrome.

Discussion
Segmental arterial mediolysis was originally named segmental mediolytic arteritis. Pathology specimens found noninflammatory lesions as the cause of this disease, and thus it was renamed segmental arterial mediolysis.4 The exact etiology of SAM is unknown, and genetic associations for this disease have not been found.3 One hypothesis is that repeated vasospasm leads to mediolysis, with arterial wall gaps that lead to arterial dissection and hemorrhage. A reparative phase begins with the formation of granulation tissue.4 The responsible pressor agent is considered to be norepinephrine. The excess of norepinephrine and its binding to the α-1

Imaging Findings
Imaging studies performed included computed tomography (CT), CT angiography (CTA), magnetic resonance angiography (MRA), and positron emission tomography (PET). Involvement of the superior mesenteric artery (n = 4) (Fig. 2) and the renal artery (n = 4) was more common followed by the celiac artery (n = 2) and the hepatic artery (n = 2) (Table 1). Dissection, pseudoaneurysm, thrombosis, and vessel wall thickening were common findings on imaging. One patient underwent a PET scan to evaluate the soft tissue surrounding the vessels and to rule out malignancy, which showed no FDG (fluoro-2-deoxy-d-glucose) uptake (Fig. 1B). In addition, one patient had hepatic infarction, and one patient had renal infarction.

Treatments
Five patients were treated with aspirin and one with apixaban followed by warfarin. Three patients were treated with antihypertensives. Beta blockers, calcium channel blockers, and angiotensin II receptor blockers were used. One patient developed a new progressively enlarging common hepatic artery aneurysm 3 months after the initial presentation and was treated endovascularly using a flow diverter. Another patient had a large right hepatic artery aneurysm at the time of the presentation in addition to other small aneurysms and vessel dissections. This large aneurysm was considered at a risk of rupture and was treated endovascularly using coil embolization.

Follow-Up
Follow-up was available in four patients and ranged from 3 to 36 months. Three months after the initial presentation, one patient developed a new common hepatic artery aneurysm (Fig. 1C, D), as described previously. Six months following endovascular treatment, the aneurysm completely resolved while the hepatic artery patency was maintained. The patient remained asymptomatic. One patient had a complete resolution of symptoms and scarring of renal infarcts and no new lesions during 6 months follow-up. One patient developed a new dissection involving the celiac artery at 3 months follow-up. The celiac artery dissection remained stable, and no new lesions developed at 36 months follow-up. Another patient was followed up for 6 months and showed a resolution of previously seen SMA thrombus.
<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)/sex</th>
<th>Clinical presentation</th>
<th>Imaging findings</th>
<th>Laboratory</th>
<th>Treatments</th>
<th>Follow-up and outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>61/M</td>
<td>Abdominal pain</td>
<td>CT of the abdomen: soft tissue around the celiac and hepatic arteries; MRA: arterial narrowing of the hepatic and celiac arteries; PET: no uptake</td>
<td>Negative ANA; Normal ESR and CRP</td>
<td>Ticagrelor; Aspirin</td>
<td>CTA at 3 mo showed pseudoaneurysm of the distal common hepatic artery</td>
</tr>
<tr>
<td>2</td>
<td>45/M</td>
<td>Right flank and groin pain</td>
<td>MRA: diffuse narrowing of the branches of the right renal artery; CTA: dissection of the right renal artery with renal infarct</td>
<td>Negative ANA, MPO antibodies, PR3 antibodies, and RF; Normal C3 and C4; Elevated ESR and CRP</td>
<td>Aspirin; Carvedilol</td>
<td>CTA at 6 mo showed no new aneurysm and scaring of the area of renal infarct</td>
</tr>
<tr>
<td>3</td>
<td>66/F</td>
<td>Nausea, vomiting, and bloody stools</td>
<td>CTA: superior mesenteric artery dissection, partially thrombosed right and left renal artery aneurysms</td>
<td>Normal ESR</td>
<td>Aspirin; Losartan; Simvastatin</td>
<td>CTA at 3 mo consistent with short segment dissection of the celiac artery; Repeat imaging at 36 mo showed no new lesions</td>
</tr>
<tr>
<td>4</td>
<td>40/M</td>
<td>Abdominal pain</td>
<td>CT: superior mesenteric artery dissection</td>
<td>Negative ANA, MPO antibodies, PR3 antibodies, RF, CCP, Jo-1, Smith, RNP, Scl-70, SSA, and SSb; Normal ESR</td>
<td>Aspirin; Metoprolol; Atorvastatin</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>73/F</td>
<td>Right upper quadrant abdominal pain, nausea, and vomiting</td>
<td>CT: right hepatic lobe infarct, pseudoaneurysms of the hepatic artery; CTA: multiple hepatic arterial aneurysms (largest in the right hepatic artery and partially thrombosed); Catheter angiography: multiple aneurysms and dissections in the celiac and superior mesenteric artery branches</td>
<td>Positive ANA (1:1280); Negative dsDNA, MPO antibodies, PR3 antibodies, Jo-1, Smith, RNP, Scl-70, SSA, SSb, and smooth muscle antibody; Elevated CRP</td>
<td>Aspirin; Diltiazem; Coil embolization of a large pseudoaneurysm (4.7 x 4 cm) originating from the right hepatic artery</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>58/M</td>
<td>Epigastric pain</td>
<td>CTA: superior mesenteric artery thrombosis and dissection, beaded appearance of the right renal artery</td>
<td>Negative ANA, MPO antibodies, PR3 antibodies, and Hepatitis B/C; Elevated CRP</td>
<td>Eliquis, warfarin</td>
<td>CTA at 6 mo with interval resolution of thrombus in the superior mesenteric artery with persistent dissection</td>
</tr>
</tbody>
</table>

Abbreviations: ANA, antinuclear antibody; anti-SSA, anti-sjogren’s syndrome A; anti-SSB, anti-sjogren’s-syndrome B; CCP, anticyclic citrullinated peptide; CRP, C-reactive protein; CTA, CT angiogram; dsDNA, double-stranded DNA; ESR, erythrocyte sedimentation rate; F, female; M, male; MPO, myeloperoxidase; MRA, magnetic resonance angiogram; PET, positron emission tomography; PR3, proteinase 3; RF, rheumatoid factor.
adrenergic receptors in the media of the vessel wall was considered responsible for causing vasoconstriction, resulting in shearing of the media from adventitia and creating arterial gaps. This hypothesis was further strengthened by Slavin and Yaeger who observed vascular changes similar to SAM in greyhound dogs after injecting ractopamine, a β-2 adrenergic agent.

The vascular bed involved in SAM is similar to that seen in other vasculitides such as polyarteritis nodosa, giant cell arteritis, and Behcet’s disease and can pose a diagnostic challenge. SAM has features that are common to those of vasculitis; however, there are clues to prompt the clinician to investigate for other etiologies. Presentation of SAM may range from pain in the involved area, such as abdominal pain, flank pain, and chest pain, to hypertension, stroke, hemorrhage, and hematochezia. Constitutional symptoms such as fatigue, fever, and weight loss that are commonly seen in inflammatory vasculitis are not seen in SAM. Unlike vasculitis, cutaneous involvement such as palpable purpura and ulcers are also not seen in SAM. Behcet’s disease is associated with recurrent oral and genital ulcers and uveitis. Giant cell arteritis may present with headache, visual changes, and jaw claudication and may have associated features of polymyalgia rheumatic with shoulder and hip girdle stiffness. Takayasu arteritis is seen in younger women who can have limb claudication and the absence of pulses. Polyarteritis nodosa may present as skin ulcerations, palpable purpura, livedo reticularis, mononeuritis multiplex, and new-onset hypertension due to renal artery involvement. Vasculitis may also be seen in systemic autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis; however, patients often will have other features of these diseases such as...
as malar rash, oral ulcers, photosensitivity, arthritis, serositis, and glomerulonephritis. Small vessel vasculitis often manifesting as cutaneous vasculitis is seen in SLE, though median and large vessel involvement has also been reported.

The inflammatory markers are usually normal or may be mildly elevated secondary to infarction and hemorrhage in SAM, whereas marked elevation of inflammatory markers is more commonly seen in vasculitis. Other features of chronic inflammation such as anemia can also be seen in vasculitis. Expanded laboratory markers may also aid in differentiating between the two entities. Positive hepatitis B serology may be seen in polyarteritis nodosa, antineutrophilic cytoplasmic antibodies (ANCA) may be seen in ANCA-associated small vessel vasculitis, and positive hepatitis C serology may be seen in cryoglobulinemic vasculitis. Vasculitis associated with systemic autoimmune diseases such as SLE will have additional serologic markers such as a positive ANA, anti-Smith, and dsDNA antibodies. Low complement levels, C3 and C4, are common with autoimmune vasculitis but not with SAM.

Segmental arterial mediolysis typically involves splanchnic vessels, whereas coronary and cerebral involvement is rare. We observed equal involvement of the renal and superior mesenteric arteries in our case series. Arterial dissection with aneurysmal dilation of the false lumen is the hallmark of SAM. Ruptured aneurysm can lead to death. Other imaging features on CT, MRA, or catheter angiography include arterial dilation, single or multiple aneurysms, hematomas, and arterial occlusion, which can lead to end-organ infarction. Intramural hematoma may give the appearance of thickened vessel wall. It should be noted that vessel wall thickening is also a common imaging finding in vasculitis. Unlike that seen in vasculitis, vessel wall thickening is not associated with wall enhancement in SAM. Similarly, active inflammatory diseases and infiltrative disorders take up FDG on PET scan and appear as hypermetabolic foci. Vessel wall thickening is not FDG-avid in SAM. Multiple aneurysms with intervening intact arterial segments can give the characteristic “string on beads” appearance in SAM. This appearance may also be seen with fibromuscular dysplasia (FMD). FMD involves the renal artery and is seen more commonly in middle-aged women unlike male predominance of SAM.

Diagnosis of SAM can be obtained by histology; however, considering the location of arterial involvement, a biopsy is not always feasible. Kalva et al proposed institutional guidelines to diagnose SAM on the basis of clinical, laboratory, and imaging findings and by excluding other possible etiologies such as vasculitis and genetic disorders (Table 2). The laboratory data in these guidelines required a negative ANA. We propose that the presence of antinuclear antibody (ANA) should not be a limiting factor in the diagnosis of SAM as isolated ANA in the absence of supporting clinical and serological data is not a marker of systemic autoimmune disease. Low titer ANA can be seen in 5% of the general population without the evidence of autoimmunity, and some studies have reported this prevalence to be as high as 27%. Clinical significance of ANA is related to the presence of various signs and symptoms of autoimmunity such as features of inflammatory arthritis, rash, glomerulonephritis, hemolytic and anemia, and laboratory data such as positive anti-Smith antibody, dsDNA, antiphospholipid antibodies, and low C3 and C4. Thus, an isolated presence of ANA in the absence of other evidence of systemic rheumatic disease should not be considered an exclusion criterion for diagnosing SAM. Similarly, an elevated ESR and CRP may often be observed with organ infarction and should not solely be used to exclude a diagnosis of SAM. Kaneko et al recently described a rare case of SAM coexisting with scleroderma.

Treatment of SAM includes conservative therapy with antiplatelet therapy, optimal blood pressure control, and endovascular interventions. It is paramount for rheumatologists and radiologists to be aware of this important mimic of vasculitis as the treatment options for these two entities are entirely different. Immunosuppressive therapy is the cornerstone of vasculitis, whereas such therapy is of no value in SAM. SAM lesions may require endovascular therapy, surgical bypass, or resection of the injured vessel. In our case series, one patient required endovascular therapy with a flow diverter, and the second patient required coil embolization of a large pseudoaneurysm. In a recent review, surveillance of eight patients with a median follow-up of 26 months showed the development of new lesions in 50% of patients. Two patients in our group developed new lesions in the arteries during follow-up, whereas one patient developed resolution of initial arterial abnormality. Data on follow-up of segmental arterial mediolysis is limited, and thus it is difficult to predict the natural course of the disease.

The diagnosis of SAM and exclusion of vasculitis are based on extensive and meticulous evaluation of the patient's symptoms, preceding events, and laboratory and imaging information, and requires a multidisciplinary approach. A modified Kalva et al criteria will improve the clinician's ability to accurately diagnose segmental arterial mediolysis and further eliminate the possibility of inaccurate diagnosis of vasculitis.

### Table 2  Institutional guidelines for the diagnosis of segmental arterial mediolysis

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>Absence of congenital predisposition for dissections (e.g., Ehlers–Danlos’ syndrome, Marfan’s syndrome, Loeys–Dietz’s syndrome) and absence of more plausible diagnosis such as fibromuscular dysplasia, collagen vascular disorder, and arthritis</td>
</tr>
<tr>
<td>Acute</td>
<td>Abdominal or flank pain, back pain, chest pain, acute hypertension, hypotension, hematuria, or stroke</td>
</tr>
<tr>
<td>Chronic</td>
<td>Abdominal pain, hypertension, hematuria, no symptoms</td>
</tr>
<tr>
<td>Imaging</td>
<td>Dissection/fusiform aneurysm/occlusion/beaded appearance/wall thickening of the mesenteric or renal arteries with or without organ infarction; no associated contiguous aortic dissection or atherosclerosis</td>
</tr>
<tr>
<td>Laboratory</td>
<td>Absence of inflammatory markers such as antinuclear antibodies and antineutrophil cytoplasmic antibodies; normal complement levels</td>
</tr>
</tbody>
</table>
Author contributions
S. B. contributed to data collection, data analysis, manuscript drafting, and revisions. A. A. contributed to data collection, data analysis, manuscript revision, and editing. E. B. and S. K. contributed to study design, data analysis, manuscript revision, and editing.

Conflicts of Interest
Dr. Kalva reports personal fees from Medtronic, Dova Pharmaceuticals, Koo Foundation, Taiwan, GE Healthcare, Springer, and Elsevier, and other from Althea Health Inc., outside the submitted work. He also reports royalties from Elsevier and Springer, consulting fees from General Electric, Medtronic Inc., and Koo Foundation, Taiwan, and research grant from AngioDynamics Inc., and is an investor in Althea Healthcare Inc. Dr. Solow reports grants from the National Institutes of Health (NIH) StopRA study, grants from the Patient-Centered Outcomes Research Institute, grants from NIH SMILE study, nonfinancial support from Janssen CNTB86 for RA, and nonfinancial support from Pfizer Tofacitinib vs TNF in RA, outside the submitted work.

Acknowledgments
None.

References
13 Nagamura N, Higuchi H. Segmental arterial mediolysis with preceding symptoms resembling viral infection hampers the differentiation from polyarteritis nodosa. Intern Med 2019;58(18):2721–2726